Search the Newsreel

Kalaris Therapeutics Releases Q2 2026 Financial Results

Kalaris Therapeutics, Inc. (ALVR) reported a narrower loss for the second quarter of 2026, with a loss of $0.48 per share, improving 21.3% from the previous year. The company's net loss for the quarter was $11.5M, reflecting ongoing efforts to manage operating expenses while …

Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results

Form 8K Kalaris Therapeutics Inc For: 11 August By Investing.com

The article reports that Kalaris Therapeutics Inc. filed a Form 8K on August 11, according to Investing.com. This filing is a significant event for the company, as 8K forms are used to announce unscheduled material events or corporate changes important to investors. The article …

BRIEF-Kalaris Therapeutics Inc Q2 Operating Income USD -12.386 Million Vs. IBES Estimate USD -12.5 Million

Kalaris Therapeutics Inc reported a Q2 operating income of -$12.386 million. This figure is slightly better than the IBES estimate of -$12.5 million. The brief financial update indicates that the company's Q2 performance, while negative, exceeded analyst expectations.

ETFs Investing in Kalaris Therapeutics, Inc. Stocks

This article identifies ETFs that hold Kalaris Therapeutics, Inc. (KLRS) stocks, providing investors with information on how to access KLRS through a more diversified and lower-risk approach. It highlights one specific fund, the Bridgeway Ultra-Small Company Market ETF (BUSM), detailing its market value, weight …

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has received an average "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $18.75. Despite this, shares remain under pressure, trading at $4.19, significantly below their 12-month high. The company recently reported a narrower-than-expected quarterly loss, …

Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% - Here's What Happened

Kalaris Therapeutics (NASDAQ:KLRS) saw its shares jump 15.4% to $4.05 in midday trading, despite lower-than-average trading volume. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $18.75. Insider activity shows Director Srinivas Akkaraju recently purchased 244,300 shares, increasing his holdings …

KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders

Abbott Cooper PLLC has initiated an investigation into Kalaris Therapeutics, Inc. (formerly AlloVir, Inc.) regarding potential breaches of fiduciary duties by its board of directors. The investigation focuses on stockholders who continuously held shares prior to November 7, 2024. The firm is offering legal …

Kalaris Therapeutics director Laurie Keating files initial beneficial ownership statement

Kalaris Therapeutics director Laurie Keating filed an initial Form 3 on August 3, 2026, disclosing her holdings as of August 1, 2026. This news brief was generated by Public Technologies (PUBT) using AI and is based on original content published by Kalaris Therapeutics Inc. …

KLRS|Kalaris Therapeutics Inc|Price:3.380|Chg%:+0.040

Kalaris Therapeutics Inc (KLRS) shows healthy fundamentals and significant growth potential, despite recent weak stock market performance. Its valuation is considered fair within the Biotechnology & Medical Research industry, and institutional ownership is very high. Analysts have rated it as a Buy with a …

Price to sales forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS

This article focuses on Kalaris Therapeutics, Inc. (NASDAQ: KLRS) and its "Price to sales forward" metric. It appears to be a financial data page from TradingView, offering an overview of the company's financials without providing detailed analysis in the content given. The page structure …

Kalaris Therapeutics Inc (KLRS) Valuation: PE, PB & Fair Value Analysis

Kalaris Therapeutics Inc (KLRS) has a current valuation score of 6.34, ranking 325 out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio is -4.24, which is significantly below its recent high and above its recent low. Key valuation metrics …

Kalaris Therapeutics Inc (KLRS) Financial Health: Profitability & Balance Sheet Analysis

Kalaris Therapeutics Inc (KLRS) has a financial score of 5.56, placing it 341 out of 385 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The article notes that relevant financial data for key metrics such as total …

Kalaris Therapeutics Inc (KLRS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Kalaris Therapeutics Inc (KLRS) focusing on its dividend history and stock split events. It states that the company has not distributed any dividends over the past five years but lists a significant merger-related stock split scheduled for January …

Kalaris Therapeutics Inc (KLRS) Cash Flow Statement

This article provides the cash flow statement for Kalaris Therapeutics Inc (KLRS), detailing its operating, investing, and financing cash flows on both quarterly and annual bases up to FY2026Q1. It includes financial figures and year-over-year percentage changes for various cash flow components. The article …

KLRS|Kalaris Therapeutics Inc|Price:3.730|Chg%:-0.190

Kalaris Therapeutics Inc (KLRS) is a clinical-stage biopharmaceutical company focusing on treatments for retinal diseases, with its stock currently priced at $3.73. The company is developing TH103, an anti-VEGF investigational therapy, which is in a Phase I clinical trial for neovascular age-related macular degeneration. …

Kalaris Therapeutics (KLRS) awards 220,000 stock options to its CFO

Kalaris Therapeutics (KLRS) has granted its Chief Financial Officer, Liisa Ann Bayko, 220,000 stock options. These options, with an exercise price of $4.00 per share and an expiration date of July 19, 2036, will vest over four years. The first 25% vests on July …

Kalaris Therapeutics appoints Liisa Bayko as CFO

Kalaris Therapeutics has appointed Liisa Bayko as its new Chief Financial Officer, bringing over 20 years of experience in biotech finance and capital markets. This appointment comes at a crucial time for the company, which is currently conducting a Phase 1b/2 clinical trial for …

Kalaris Therapeutics stock falls despite naming new CFO

Kalaris Therapeutics Inc. (NASDAQ: KLRS) shares dropped 6.4% on Monday despite the announcement of Liisa Bayko as the company’s new Chief Financial Officer. Bayko brings over 20 years of biotechnology finance experience to the biopharmaceutical company, which is currently enrolling patients in its Phase …

Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer

Kalaris Therapeutics, Inc. announced the appointment of Liisa Bayko, MBA, as Chief Financial Officer, strengthening its leadership team with her 20+ years of biotechnology finance expertise. Bayko, previously a top-ranked biotechnology analyst at Evercore ISI, will help advance Kalaris' clinical development efforts for its …

Kalaris Therapeutics, Inc. Announces Appointment of Liisa Bayko to Chief Financial Officer, Effective July 20, 2026

Kalaris Therapeutics, Inc. has announced the appointment of Liisa Bayko, MBA, as its new Chief Financial Officer, effective July 20, 2026. Ms. Bayko brings over two decades of experience in biotechnology finance, strategy, and capital markets, having previously served as Managing Director, Biotech Equity …

Kalaris: 29% received no anti-VEGF for six months after one injection

Kalaris Therapeutics reported positive Phase 1a clinical trial data for their TH103 treatment for neovascular age-related macular degeneration (AMD). The data, covering 17 treatment-naive and 3 treatment-experienced patients, showed structural and functional improvements, with 29% of treatment-naive patients not requiring additional anti-VEGF therapy for …

Enterprise value to revenue forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS

This article provides financial information for Kalaris Therapeutics, Inc. (NASDAQ: KLRS), specifically focusing on its enterprise value to revenue forward. It notes that the market is currently closed with no trades. The content seems to be a financial data page from TradingView, offering an …

Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Kalaris Therapeutics Inc. (KLRS) stock on NASDAQ, showing a current price of $4.61 with a decrease of 7.59%. It notes that there are currently no analyst ratings or earnings information available for the company. The page …

KLRS Slides As Traders Digest Weak Cash Burn Metrics

KLRS Stock Dips As Traders Weigh Cash Burn And Volatility

Kalaris Therapeutics (KLRS) stock experienced a -6.48% dip due to negative sentiment following a clinical trial setback. The company, a micro-cap biotech, shows strong liquidity with $97.2M in cash but faces significant cash burn and deep negative returns, making it a speculative, high-volatility trading …

KLRS Stock Pops As Kalaris Maps Out TH103 Catalysts

Kalaris Therapeutics Inc. (KLRS) surged 15.4% due to pivotal clinical trial success for its lead drug TH103, currently in trials for neovascular age-related macular degeneration. The company plans to present Phase 1a data at ASRS 2026 and expects initial Phase 1b/2 data in the …

Kalaris Says Additional Patients Show Improved Vision in Phase 1a Trial in Neovascular AMD

Kalaris Inc. announced that additional patients in its Phase 1a clinical trial for neovascular age-related macular degeneration (nAMD) demonstrated improved vision. The company's lead drug candidate, KAL-101, is being investigated for its potential to offer a new treatment option for this severe eye condition. …

Kalaris Therapeutics Reports Positive Expanded Phase 1a Data for TH103 in Neovascular AMD

Kalaris Therapeutics announced positive expanded Phase 1a data for its TH103 treatment for neovascular age-related macular degeneration (AMD), showing improvements in vision and retinal health with extended treatment durability. The company is currently enrolling patients for a Phase 1b/2 trial, with preliminary data anticipated …

Kalaris shares additional Phase 1a data for AMD treatment TH103

Kalaris Therapeutics Inc. presented additional Phase 1a data for its AMD treatment TH103, showing promising results in extending retreatment intervals for both treatment-naive and treatment-experienced patients. The company reported a favorable pharmacokinetic profile suggesting greater intraocular retention and is currently enrolling patients for its …

Why Is Kalaris Therapeutics Stock Gaining Friday?

Kalaris Therapeutics (KLRS) stock gained nearly 18% on Friday after the company announced expanded data from its Phase 1a trial for TH103, an experimental treatment for neovascular age-related macular degeneration. The expanded results showed vision improvements, enhanced retinal anatomy, and extended durability with strong …